Gaps in the information shared on consumer healthcare products

Makiko Hayashi¹, Shintaro Sengoku², Sakuo Hoshi¹*, Hiromichi Kimura¹

¹ Pharmaco-Business Innovation Laboratory, Graduate School of Pharmaceutical Science, The University of Tokyo, Tokyo, Japan; ² Innovation Management Science Laboratory, The University of Kyoto, Kyoto, Japan.

ABSTRACT: We conducted a questionnaire survey of visitors to the Japan Drugstore Show 2006 and an additional questionnaire survey of pharmacists in 2008 to ascertain the current information gaps between consumers and manufacturers of consumer healthcare products (CHPs). Three main gaps were apparent: first was a gap between information that consumers wanted to receive and information that was widely disclosed by manufacturers of CHPs, second was a gap between the advisors whom consumers regarded as appropriate and the advisors who consumers had actually consulted, and a gap between what consumers expect pharmacists to know and pharmacists' actual knowledge. Manufacturers' efforts alone will not be able to close these gaps because of the number of regulations. Thus, a new social system should be constructed to supply adequate information on CHPs and consumers should enjoy free access to this information.

Keywords: Consumer healthcare product, information sharing, gap

1. Introduction

Recently, more Japanese have become conscious of their health. The rapid aging of Japanese society unlike that in any other country may be a driving force behind these health concerns. A new health examination focusing on metabolic syndrome that started in April 2008 may also affect concerns about health. As a result, the market for health-related products has grown rapidly. The Ministry of Economy, Trade and Industry (METI) has estimated that the market for consumer healthcare products (CHPs) had reached 1.3 trillion yen in 2000 and will expand to about 3.2 trillion yen in 2010 (1). CHPs have now become a popular part of daily life. However, such a rapid growth in CHPs also causes trouble for consumers. Some CHPs have evidence indicating their efficacy at improving health, but others have dubious efficacy, safety, and quality. The confusion over foods for specific health uses, i.e. "health foods," may be one factor for this trouble. That is, foods for specific health uses are regulated by the METI, while "health foods" (Table 1) are simply "food," so permission, approval, and notification for their labeling claims are not regulated by the METI. Therefore, each consumer must obtain information on "health foods" and evaluate their efficacy, safety, and quality individually. That said, only a few consumers appear able to evaluate "health foods" correctly on the basis of adequate information. Most consumers seem to be influenced just by information deluging them without being able to evaluate those foods.

The Internet now allows free, instant access to news sources around the world with regard to CHPs. That said, some information seems to have dubious reliability and to contain exaggerated advertisements. Such information may cause consumer misunderstanding with regard to the efficacy, safety, and quality of CHPs. The following are examples of confusion-causing statements: "Some diseases can be treated by some CHPs," "The more we take CHPs, the more effective CHPs are," "CHPs cannot be harmful to humans because they are health food," and "All CHPs are officially guaranteed to be safe because they are marketed as health foods." Such statements are why some CHPs actually cause problems with consumer health.

Under these circumstances, the Ministry of Health, Labour and Welfare (MHLW) enhanced the regulatory and guidance systems for CHPs (2-7). In 2002, the MHLW issued a notice to promote the training of advisory personnel with special knowledge about CHPs (8). In the same year, the National Institute of Health and Nutrition, an "independent policy corporation," established a public qualification system for Nutrition Representatives. The MHLW has also reviewed systems for regulating CHPs since 2003 and established guidelines to manage the safety of CHPs in tablets or capsules in 2005 (7). These guidelines are expected to improve CHPs manufacturers' risk management and to
perhaps also improve consumers’ awareness of the risks of CHPs. That said, the rapid growth and expansion of the CHP market of and its rich variety of products, including foreign imports, mean that there should be limitations to regulate the wide variety of CHPs in accordance with the same guidelines.

Thus, the current study surveyed consumers to ascertain problems with CHPs. A questionnaire was distributed at the Japan Drugstore Show 2006, and several gaps in information sharing with regard to CHPs became apparent. An additional questionnaire was distributed among pharmacists in 2008. Another gap in the information sharing with regard to CHPs also became apparent. The results of the surveys are reported here, and a new way to eliminate gaps in information sharing with regard to CHPs is proposed.

2. Materials and Methods

The Japan Drugstore Show 2006 was held on February 11, 2006 at Makuhari in Chiba Prefecture. A questionnaire was distributed to the visitors of the Japan Drugstore Show. The completed survey was collected on the same day. Visitors were asked about (i) their individual attributes (gender, age, and occupation), (ii) their purchase histories with regard to CHPs, (iii) their motives for purchasing CHPs, (iv) the route by which they purchased CHPs, and (v) how they obtained information about CHPs. As a result of that survey, an additional questionnaire was distributed to new pharmacists at Ain Pharmacies, Ltd. on May 12, 2008. The completed survey was collected on the same day. This survey focused on the pharmacists’ purchase histories and knowledge of CHPs. Table 1 shows the categories of CHPs.

3. Results

A total of 515 questionnaires was distributed to the visitors of the Japan Drugstore Show held on February 11, 2006 and a total of 501 responses was received, indicating a response rate of 97.3%. Of the 501 respondents, 134 were men (26.7%) and 367 were women (73.3%); 15 were teens (over 15 years old) (3.0%), 82 were in their twenties (16.4%), 101 were in their thirties (20.2%), 72 were in their fifties (14.4%), and 75 were over sixty (14.9%). Most respondents were housewives (36.9%). Age and occupation distributions are shown in Figure 1.

A total of 28.1% of respondents bought certain CHPs regularly, a total of 17.1% of respondents bought certain CHPs irregularly, a total of 21.5% of respondents bought different CHPs, and a total of 33.3% of respondents did not buy any CHPs (Figure 2). The age and occupation distributions were similar for each group (data not shown). Most people bought CHPs at drugstores and mainly received information about CHPs from drugstores, TV, and the Internet. Manufacturers or manufacturers’ web sites were seldom used as sources of information on CHPs (Figure 3).

People mainly consulted with medical doctors, dentists, pharmacists, and other users. They wanted
to consult with advisory personnel though seldom did so (Figure 4). People obtained information on CHPs mainly in regard to the efficacy and safety of specific products or specific components or about the reputations of specific products or specific components (Figure 5). People who bought certain CHPs regularly or irregularly tended to obtain more information about efficacy than people who bought different CHPs or who did not buy CHPs (data not shown).

A total of 158 questionnaires was additionally distributed to new pharmacists at Ain Pharmacies, Ltd. on May 12, 2008. Of the 158 respondents, 77 were men (48.7%) and 81 were women (51.3%); 153 were in their twenties (96.8%) and 5 were in their thirties (3.2%). A total of 5.2% of respondents bought certain CHPs regularly, a total of 22.4% of respondents bought certain CHPs irregularly, a total of 39.7% of respondents bought different CHPs, and a total of 32.7% of respondents did not buy any CHPs (Figure 6). Though 96.2% of those pharmacists knew the names of CHPs, only 38.0% of the pharmacists could explain the categories of CHPs (data not shown), and only 10.9% indicated that they could explain the effects of CHPs (Figure 7). Those who were able to explain about CHPs obtained their knowledge mainly from lectures at university, followed by TV or magazines (data not shown).
4. Discussion

In Japan, an increase in health consciousness is thought to have resulted in a rapid expansion of the market for CHPs, though the market is reaching maturity. That said, the market will expand again as a result of a new mandatory health checkup system (health checkup/half year limit) focusing on metabolic syndrome that was introduced in April 2008. Of course, manufacturers’ effort have also contributed to the expansion of the market for CHPs. For example, Calpis Co., Ltd. has spent ten years evaluating the efficacy and safety of Ameal S® a food for specific health uses (9). Otsuka Pharmaceutical Co., Ltd. chartered an airplane and conducted simulations on a long-distance international flight to evaluate the health effects of Pocari Sweat® in terms of preventing a traveler’s thrombosis (economy class syndrome) (9, 10). Such manufacturers’ efforts should contribute to the prevalence of CHPs and their sound use. That said, there are also a number of reported cases where CHPs caused harm (11).

Many questionnaires have surveyed consumers about their knowledge and use of CHPs (12-15). To the extent known, however, no questionnaires have surveyed consumers about their awareness of CHPs to investigate gaps between consumers and manufacturers. The current study conducted questionnaire surveys regarding CHPs to specifically investigate information gaps between consumers and manufacturers. In this study, CHPs were used under the broad categories shown in Table 1. General foods, drugs, and quasi-drugs were excluded from consideration. This study did not separate CHPs according to the categories shown in Table 1 but considered them as a whole. This was because consumers were considered to be generally unaware of the categories of CHPs themselves. That view was supported by the results of an additional questionnaire for pharmacists. Less than 40% of the pharmacists knew the categories of CHPs (data not shown). Consumer unawareness of the categories of CHPs may also cause gaps in information sharing with regard to CHPs, so a survey separating CHPs by category is planned for the near future.

The current study showed that respondent attributes included different age groups and various occupations, but females, respondents in their thirties, and housewives were dominant (Figure 1). In the actual market, slightly more females buy supplements than males (16, 17). Thus, the current study may somewhat highlight the opinions of females. The data showed that about 70% of consumers bought CHPs and about 30% of consumers bought certain CHPs regularly (Figure 2). Consumers bought CHPs mainly at drugstores and obtained information about CHPs mainly at drugstores or from TV and the Internet. Manufacturers’ web sites, which were thought to be rich in information, were the least used source (Figure 3). In this study, consumers were more interested in the "efficacy and safety" of "each CHP" while they were less interested in the "reputations" of "each component of a CHP" (Figure 5). With "health foods", however, manufacturers are restricted in terms of labeling or advertising of health claims by the Pharmaceutical Affairs Law. Only on functional nutritional foods and specific health uses are manufacturers permitted to label or advertise nutrition claims. In short, manufacturers of CHPs are usually unable to provide consumers with information on the health effects of their products. This is why few consumers obtain information directly from manufacturers (Figure 3). Obviously, however, manufacturers of CHPs have the most information on those products. Thus, one can conclude that there is a gap between information that consumers want and information that manufacturers can provide. Needless to say, regulations should exist, but manufacturers should be better utilized as resources.

Medical doctors or dentists, pharmacists, and advisory personnel were advisors for CHPs who consumers felt were appropriate for consultation. Of these individuals, advisory personnel should be most appropriate since they have received specific training in CHPs, but advisory personnel were actually consulted the least (Figure 4). Given the great variety of CHPs on the market and the huge amount of information on CHPs deluging consumers, consumers should take advantage of advisory personnel since they are well versed in CHPs. They know, for instance, what each component of a CHP does and its effectiveness and how to use the CHPs and they can provide consumers with correct and adequate information on CHPs. The MHLW is promoting the training of advisory personnel (8), and Japan now has more than ten training systems for advisory personnel, national training systems, public training systems, and private training systems. The results of the current study, however, indicate that consumers consult medical doctors or pharmacists rather than advisory personnel. That may be because advisory personnel are not qualified and not well known. Thus, there is a gap between the advisors that consumers actually consult and the advisors that consumers consider appropriate.

An additional survey showed that about 70% of pharmacists bought some CHPs, which was at almost the same rate as general consumers. Fewer pharmacists regularly bought certain CHPs, i.e. 5.2% of pharmacists bought certain CHPs regularly while 28.1% of general consumers did (Figures 2 and 6). Moreover, pharmacists were considered an appropriate source of information by consumers, but in reality only 38.0% of pharmacists knew the categories of CHPs (data not shown) and only 10.9% were able to explain the health effects of CHPs (Figures 4 and 7). Thus, there is a gap between what consumers expect pharmacists to know and pharmacists’ actual knowledge.
In conclusion, three gaps were identified. First was the gap between information that consumers want and information that manufacturers can provide, second was the gap between the advisors that consumers actually consulted and the advisors that consumers considered appropriate, and third was the gap between what consumers expected pharmacists to know and pharmacists' actual knowledge. Several steps could be taken to close these gaps. Lectures on CHPs should be included in the curricula of medical and pharmaceutical courses more often and incentives to study CHPs should be given. Qualifications for advisory personnel should be established and standardized. If possible, advisory personnel should be obligatory at drug stores. Qualified salespersons will be obligatory at drug stores, so education of those salespersons in CHPs should be an effective solution.

Needless to say, CHP advertisement should be regulated under the current law. That said, manufacturers may be intentionally flooding the Internet with questionable information or exaggerated advertisements. Moreover, many CHPs are now being imported officially and individually in today's borderless world. Voluntary management by manufacturers should have limitations. Finally, current consumer centers in Japan should allow consumers free access and inform them of what is correct and what is wrong with CHPs. All permitted information should be provided, regardless of whether there is evidence or not, pursuant to regulations for specialists at consumer centers. If consumer centers cannot fulfill this role, a center to provide comprehensive information on CHPs should be established. In addition to establishing an information provision system, consumers should be correctly informed of the categories of CHPs since 38.0% of pharmacists knew the categories of CHPs (data not shown). The newly established consumer affairs office should take the initiative in providing appropriate information on CHPs.

In the current study, only a domestic survey was performed. Of course, similar gaps in the information sharing with regard to CHPs are likely to exist in the United States. In the United States, however, foods are simply categorized as conventional foods and dietary supplements, so there are no such categories of CHPs as exist in Japan. Furthermore, forms of dietary supplements are restricted to pills, tablets, capsules, or liquids. Additionally, labels on dietary supplements are legally required. Thus, gaps in information sharing with regard to CHPs are assumed to be smaller than those with regard to CHPs. The authors intend to focus on gaps in information sharing with regard to CAM in the near future.

Acknowledgements

The authors wish to thank Ms. Kaoru Hidaka, a researcher at the Pharmaco-Business Innovation Laboratory (currently Director of Veritas Management, Ltd.) for her cooperation with this survey, and Dr. Hirobumi Ohama and Ms. Hideko Ikeda of the Japanese Institute for Health Food Standards for their helpful suggestions. The authors also wish to thank Drs. Takashi Inoue and Kunihiro Musashi of the NPO Medical Venture Conference for their advice regarding the survey results. Finally, the authors wish to thank Matsumoto Kiyoshi, Ltd. and Ain Pharmacies, Ltd. for their cooperation with surveillance.

References

8. Standard policy of training of advisory staff for food for


(Received February 4, 2009; Revised March 13, 2009; Accepted March 17, 2009)